BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.65 USD
-0.03 (-4.83%)
Updated May 10, 2024 03:58 PM ET
After-Market: $0.66 +0.01 (1.23%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 81 - 100 ( 202 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Analyst Day Recap; Assets, Data and Collaborations Drive Long Term Vision
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Healthcare - The A to Z of HSCT: InvestorÂ’s guide to Hematopoietic Transplant Medicine
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040/Keytruda Study Gets Going as Expected; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Path Forward for BL-8040 Continues to Look Bright To Us; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040 Immunotherapy Push Forward Continues with Roche
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q16 Results; Projected Significant Drivers by Year-End
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q16 Results; Building the ''8040 Database and Regulatory Path Forward
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
More Patients; Consistent Positive CR/CRi; Momentum Building
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
The Year of ''8040; Imminent Phase IIa`AML Data; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2015 Results; Imminent r/rAML ''8040 Update; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Important Visibility In Hand for BL-7010; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.